173 related articles for article (PubMed ID: 38384968)
21. Risk factors of bone metastasis in patients with newly diagnosed prostate cancer.
Chaoying L; Chao M; Xiangrui Y; Yingjian H; Gang Z; Yunhan R; Yu G
Eur Rev Med Pharmacol Sci; 2022 Jan; 26(2):391-398. PubMed ID: 35113414
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen.
Kataoka A; Yuasa T; Kageyama S; Tsuchiya N; Habuchi T; Iwaki H; Narita M; Okada Y; Yoshiki T
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):480-4. PubMed ID: 16909972
[TBL] [Abstract][Full Text] [Related]
23. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
24. [Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].
Wang TY; Chen XP; Li XS; Jia Yx; Cheng J; Zhang JH; Cai L; Zhang Z; Gong K; He ZS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 44(4):528-34. PubMed ID: 22898839
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL.
Chang CC; Lee YC; Tsai HW; Yii SC; Yen TH; Chu FY
Asian Pac J Cancer Prev; 2015; 16(13):5261-4. PubMed ID: 26225663
[TBL] [Abstract][Full Text] [Related]
26. Role of serum prostate-specific antigen as predictor for bone metastases in newly diagnosed prostate cancer.
Singh OP; Yogi V; Redhu P; Ghori HU; Pareek A; Lal N
J Cancer Res Ther; 2019 Mar; 15(Supplement):S39-S41. PubMed ID: 30900618
[TBL] [Abstract][Full Text] [Related]
27. Serum ProGRP as a novel biomarker of bone metastasis in prostate cancer.
Yu M; Yang C; Wang S; Zeng Y; Chen Z; Feng N; Ning C; Wang L; Xue L; Zhang Z
Clin Chim Acta; 2020 Nov; 510():437-441. PubMed ID: 32791134
[TBL] [Abstract][Full Text] [Related]
28. Determination of the optimal cut-off value of serum prostate-specific antigen in the prediction of skeletal metastases on technetium-99m whole-body bone scan by receiver operating characteristic curve analysis.
Manohar PR; Rather TA; Khan SH
World J Nucl Med; 2020; 19(3):255-259. PubMed ID: 33354181
[TBL] [Abstract][Full Text] [Related]
29. Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection.
Ferrer-Batallé M; Llop E; Ramírez M; Aleixandre RN; Saez M; Comet J; de Llorens R; Peracaula R
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420168
[TBL] [Abstract][Full Text] [Related]
30. Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.
Tumminello FM; Badalamenti G; Incorvaia L; Fulfaro F; D'Amico C; Leto G
Med Oncol; 2009; 26(1):10-5. PubMed ID: 18461289
[TBL] [Abstract][Full Text] [Related]
31. Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.
Metwalli AR; Rosner IL; Cullen J; Chen Y; Brand T; Brassell SA; Lesperance J; Porter C; Sterbis J; McLeod DG
Urol Oncol; 2014 Aug; 32(6):761-8. PubMed ID: 24929891
[TBL] [Abstract][Full Text] [Related]
32. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan.
Kosuda S; Yoshimura I; Aizawa T; Koizumi K; Akakura K; Kuyama J; Ichihara K; Yonese J; Koizumi M; Nakashima J; Fujii H
Cancer; 2002 Feb; 94(4):964-72. PubMed ID: 11920464
[TBL] [Abstract][Full Text] [Related]
33. MRI-based texture analysis of the primary tumor for pre-treatment prediction of bone metastases in prostate cancer.
Wang Y; Yu B; Zhong F; Guo Q; Li K; Hou Y; Lin N
Magn Reson Imaging; 2019 Jul; 60():76-84. PubMed ID: 30917943
[TBL] [Abstract][Full Text] [Related]
34. [Low serum testosterone level does not predict bone metastasis of prostate cancer].
Li XB; Zhang L; Rao TW; Chen J; Leng YJ; Huang P
Zhonghua Nan Ke Xue; 2017 Mar; 23(3):212-216. PubMed ID: 29706040
[TBL] [Abstract][Full Text] [Related]
35. How many bone metastases may be defined as high-volume metastatic prostate cancer in Asians: A retrospective multicenter cohort study.
Yamada Y; Sakamoto S; Rii J; Yamamoto S; Kamada S; Imamura Y; Nakamura K; Komiya A; Nakatsu H; Ichikawa T
Prostate; 2020 Apr; 80(5):432-440. PubMed ID: 32017175
[TBL] [Abstract][Full Text] [Related]
36. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
37. Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial.
Buelens S; Poelaert F; Dhondt B; Fonteyne V; De Visschere P; Ost P; Verbeke S; Villeirs G; De Man K; Rottey S; Decaestecker K; Lumen N
Urol Oncol; 2018 Apr; 36(4):158.e13-158.e20. PubMed ID: 29336978
[TBL] [Abstract][Full Text] [Related]
38. The value of pretreatment clinical and biochemical parameters in patients with newly diagnosed untreated prostate carcinoma and no indications for bone metastases on the bone scintigram.
Stokkel M; Zwinderman A; Zwartendijk J; Pauwels E; van Eck-Smit B
Eur J Nucl Med; 1997 Oct; 24(10):1215-20. PubMed ID: 9323261
[TBL] [Abstract][Full Text] [Related]
39. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?
Wolff JM; Zimny M; Borchers H; Wildberger J; Buell U; Jakse G
Eur Urol; 1998; 33(4):376-81. PubMed ID: 9612680
[TBL] [Abstract][Full Text] [Related]
40. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
